JB/CALL/GILEAD SCIENCES/75/0.05/21.03.25 | Market Closed - Swiss Exchange 08:50:00 24/06/2024 pm IST | ||
| 0.25 CHF | +4.17% |
|
| Current month | +150.00% | ||
| 1 month | +92.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.25 | +4.17% |
| 21/24/21 | 0.24 | +50.00% |
| 20/24/20 | 0.16 | +60.00% |
| 19/24/19 | 0.1 | -9.09% |
| 18/24/18 | 0.11 | -8.33% |
Delayed Quote Swiss Exchange
Last update June 24, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Bank Julius Bär |
| GIYEJB | |
| ISIN | CH1303727544 |
| Date issued | 28/11/2023 |
| Strike | 75 $ |
| Maturity | 21/03/2025 (270 Days) |
| Parity | 20 : 1 |
| Emission price | 0.4 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.75 CHF |
|---|---|
| Lowest since issue | 0.1 CHF |
| Spread | 0.01 CHF |
| Spread % | 3.85% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.73
USD
Average target price
82.89
USD
Spread / Average Target
+17.19%
- Stock Market
- Warrants
- GIYEJB Warrant
